Bioxytran (BIXT) Emerging Growth Conference 83 summary

Platform technology updates

• Three platform technologies: broad-spectrum oral antiviral, oxygenation molecule for stroke, and a cancer metastasis treatment were highlighted, all developed using AI.

• The oral antiviral achieved 100% viral reduction in seven days in clinical trials and targets COVID-19, influenza, and RSV.

• The oxygenation molecule benefits from camel hemoglobin, offering a more robust feedstock and scalability for production.

• The cancer platform is positioned for future development and licensing opportunities, with active preparation for meetings in Japan.

• The company is seeking collaboration partners for FDA trials and exploring government funding opportunities.

Industry and competitor analysis

• Galectin science is gaining attention, with a competitor's drug showing statistical significance in two clinical trials and a $6 price target from H.C. Wainwright.

• A valuation rift exists among galectin antagonist companies, with significant differences in market cap and cash positions.

• The company claims best-of-breed technology with multiple disease indications and pristine clinical trial data.

• Investors are encouraged to consider a bear trade due to perceived undervaluation compared to competitors.

• The rising tide of galectin science is expected to benefit all companies in the space.

Strategic initiatives and future outlook

• Licensing efforts are underway in Japan, with multiple slide decks prepared for cancer, virology, dermatology, and organ indications.

• University of Georgia may use the product in a USDA grant-funded clinical trial, and Arizona State is publishing research on galectin-3 staining as a companion diagnostic.

• The company is focused on shareholder alignment and milestone achievement, aiming to attract new investors and funding.

• The product pipeline includes advanced candidates like ProLectin-M and ProLectin-I, as well as the oxygen carrier.

• The company emphasizes the potential for significant healthcare savings and increased responder rates through its diagnostics and therapeutics.